Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
NCT05316480
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Neuroendocrine Neoplasm
Interventions
DRUG:
Nimotuzumab
Sponsor
Fudan University